PP_1170x120_10-25-21

patients with atrial fibrillation/atrial flutter

Aurobindo receives FDA approval for dofetilide capsules

Aurobindo receives FDA approval for dofetilide capsules

EAST WINDSOR, N.J. — Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for Dofetilide Capsules, 0.125 mg, 0.25 mg, and 0.5 mg. Aurobindo’s dofetilide capsules are an AB-rated generic equivalent to the reference listed drug, Pfizer’s Tikosyn. Dofetilide capsules are indicated for the maintenance of normal sinus